Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients
- PMID: 31493541
- PMCID: PMC6942208
- DOI: 10.1016/j.bbmt.2019.08.022
Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients
Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated the ability of a comprehensive geriatric assessment (CGA) to predict post-alloHCT outcomes in a single-center prospective cohort study of patients age 50 years and older. Outcomes included overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM). A total of 148 patients were included, with a median age of 62 years (range, 50 to 76 years). In multivariate regression analysis, several CGA measures of functional status were predictive of post-alloHCT outcomes, after adjusting for traditional prognostic factors. Any deficit in instrumental activities of daily living (IADL) was associated with inferior OS (hazard ratio [HR], 1.81, 95% confidence interval [CI], 1.07 to 3.08; P = .03) and PFS (HR, 1.85; 95% CI, 1.15 to 2.99; P = .01). A Medical Outcomes Study Physical Health scale (MOS-PH) score <85 was associated with inferior OS (HR, 1.96; 95% CI, 1.13 to 3.40; P = .02), PFS (HR, 1.75; 95% CI, 1.07 to 2.88; P = .03), and increased NRM (subdistribution HR, 2.57; 95% CI, 1.12 to 5.92; P = .03). MOS-PH score was also associated with the number of non-hematologic grade ≥3 adverse events within the first 100 days after alloHCT (rate ratio, 1.61; 95% CI, 1.04 to 2.49; P = .03). These findings support previous work suggesting that IADL is an important prognostic tool prior to alloHCT. MOS-PH is newly identified as an additional metric to identify older patients at higher risk of poor post-alloHCT outcomes, including toxicity and NRM.
Keywords: Allogeneic transplantation; Functional status; Geriatric assessment.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures


Similar articles
-
Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.Transplant Cell Ther. 2022 Jun;28(6):309.e1-309.e9. doi: 10.1016/j.jtct.2022.02.022. Epub 2022 Mar 3. Transplant Cell Ther. 2022. PMID: 35247612 Free PMC article.
-
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.Blood Adv. 2020 Jun 23;4(12):2810-2820. doi: 10.1182/bloodadvances.2020001719. Blood Adv. 2020. PMID: 32574365 Free PMC article.
-
Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults.Transplant Cell Ther. 2021 Apr;27(4):344.e1-344.e5. doi: 10.1016/j.jtct.2021.01.001. Epub 2021 Jan 7. Transplant Cell Ther. 2021. PMID: 33836888
-
Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.Blood. 2019 Dec 5;134(23):2013-2021. doi: 10.1182/blood.2019001300. Blood. 2019. PMID: 31805199 Review.
-
Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis.Medicine (Baltimore). 2018 Jul;97(27):e10310. doi: 10.1097/MD.0000000000010310. Medicine (Baltimore). 2018. PMID: 29979374 Free PMC article. Review.
Cited by
-
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.Pharmaceutics. 2023 Dec 29;16(1):55. doi: 10.3390/pharmaceutics16010055. Pharmaceutics. 2023. PMID: 38258066 Free PMC article. Review.
-
Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.Transplant Cell Ther. 2022 Jun;28(6):309.e1-309.e9. doi: 10.1016/j.jtct.2022.02.022. Epub 2022 Mar 3. Transplant Cell Ther. 2022. PMID: 35247612 Free PMC article.
-
Allogeneic Transplantation for Older Adults.Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2. Adv Exp Med Biol. 2025. PMID: 40488822 Review.
-
Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults.Transplant Cell Ther. 2021 Jul;27(7):617.e1-617.e7. doi: 10.1016/j.jtct.2021.03.028. Epub 2021 Apr 6. Transplant Cell Ther. 2021. PMID: 33836312 Free PMC article.
-
Association of Patient-Reported Physical Activity on Allogeneic Hematopoietic Cell Transplant Outcomes.Clin Hematol Int. 2021 Mar 4;3(1):34-39. doi: 10.2991/chi.k.210221.001. eCollection 2021 Mar. Clin Hematol Int. 2021. PMID: 34595465 Free PMC article.
References
-
- Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975–2015, National Cancer Institute; [cited; based on November 2017 SEER data submission, posted to the SEER web site, April 8]. Available from: https://seer.cancer.gov/csr/1975_2015/
-
- D’Souza A, Fretham C. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, available at www.cibmtr.org. 2018.
-
- Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, et al. Allogeneic Stem Cell Transplantation for Patients Age >/= 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017. January;23(1):44–52. - PubMed
-
- McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. April 10;28(11):1878–87. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials